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Introduction 
Of the approximately 3.2 million children with HIV globally, 90% live in sub-Saharan Africa.[1] The global 
expansion of prevention of mother-to-child HIV transmission and scale up of antiretroviral therapy (ART) 
programs has resulted in a substantial decrease in the number of infants born with HIV and an increase in 
numbers of older children and adolescents living with HIV due to improved survival on ART.[2]  
While ART has dramatically decreased the risk of opportunistic infections and mortality, there is mounting 
evidence that longstanding HIV infection and/or its treatment are associated with non-infectious 
complications, including cardiac disease.[3] Cardiac disease has been reported among treated and untreated 
HIV-infected adults, with prevalence ranging from 18-78%.[4, 5] Low CD4 cell count and high viral load 
have been identified as independent risk factors for cardiac disease, but residual confounding by well-
recognised traditional risk factors such as smoking and hypertension remain an issue in these studies.[5] A 
small number of studies have suggested that children with HIV also are at risk of cardiac disease, despite 
the absence of traditional risk factors, with the most common reported abnormalities being left ventricular 
(LV) dilatation and systolic dysfunction.[6, 7] HIV infection can also lead to right heart abnormalities, 
either as a consequence of pulmonary arterial hypertension (PAH) or secondary to chronic lung disease. 
We have previously reported a high prevalence of chronic lung disease among HIV-infected older children 
on ART[8, 9], which may result in pulmonary hypertension and subsequent right ventricular (RV) dilatation 
and/or RV systolic dysfunction.[10] However, most studies were conducted in children on zidovudine 
monotherapy or in mixed cohorts of ART-naive and experienced participants, and were mainly performed 
in younger children in high-resource settings.[7, 11]  
In the ART era, there are contrasting reports on cardiac disease in HIV-infected children who are on ART 
from high and low-resource settings.[12-14] We therefore investigated the prevalence, spectrum and risk 
factors for cardiac abnormalities in children established on ART in Harare, Zimbabwe. 
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Methods 
A cross-sectional study was conducted at the pediatric HIV clinic at Harare Central Hospital, Zimbabwe, 
between August 2014 and June 2015. Harare Central Hospital is the largest public-sector hospital in Harare 
and provides HIV care to over 4000 children. This study was conducted within a larger cohort study called 
INHALE (Investigation of Heart and Lung Diseases in HIV among older children), aiming to investigate 
cardiorespiratory disease in children with HIV infection. Findings of the clinical and radiographic features 
of chronic lung disease have already been published.[8, 9] This report is limited to echocardiographic 
abnormalities in the same cohort of HIV-infected children.  
HIV-infected children aged 6-16 years attending for HIV care, not acutely ill and taking ART for at least 
six months, were consecutively recruited on week days, restricted to the first five eligible participants per 
day for logistical ease. A minimum of 6 months on ART was selected to enable sufficient time for viral 
suppression and for the risk of immune reconstitution syndrome to have dropped.  
 Study procedures 
An interviewer-administered questionnaire was used to collect socio-demographic data and clinical history, 
including previous illnesses, drug history and current symptoms. A standardized clinical assessment was 
performed, including anthropometric measurement (height and weight), heart rate, respiratory rate, blood 
pressure, New York Heart Association (NYHA) functional class, pulse oximetry and Medical Research 
Council (MRC) Dyspnoea scale.  Fasted blood was collected for measurement of plasma glucose, and for 
HIV-1 viral load and CD4 count testing. The CD4 count was measured on site using an Alere PIMA 
analyser (Alere Technologies GmbH, Jena, German) and plasma VL was measured using the COBAS 
protocol Ampliprep/Taqman 48 Version 2.0 (Roche Molecular System, Branchburg, USA). Spirometry was 
performed according to American Thoracic Society guidelines to assess respiratory function.[15]  
A transthoracic echocardiogram was performed using a Mindray DC N6 multipurpose ultrasound machine 
(Mindray, Shenzhen, China) by an echocardiographer trained in pediatric echocardiography (EM). A 
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standard protocol consisting of 2-dimensional, M-mode, pulsed and continuous wave Doppler and colour 
flow mapping as recommended for transthoracic echocardiography was adopted [16]. Participants were 
scanned in the left lateral or supine position to obtain an optimum image quality and all measurements made 
over three cardiac cycles. Images were acquired using a 7MHz transducer and were saved in DICOM format 
for off-line analysis. Cardiac measurements were based on the American Society of Echocardiography 
(ASE) criteria [16]. Echocardiography scans were quality controlled by an experienced pediatric 
cardiologist (JPK) for adequacy of views. Furthermore, a random sample of 10% scans were re-measured 
by an independent rater (MSP) for interobserver agreement.  
Definitions 
Echocardiography measures for LV and right ventricular (RV) dimensions were normalized to body surface 
area calculated using Du Bois and Du Bois formula,[17] and converted to z-scores using local 
references[18] and further compared to European published references among Caucasian children.[19] 
Local reference ranges were used as the primary basis for defining cardiac abnormalities in the study. LV 
and RV dilatation were defined as a z-score >+2 for LV and RV diameter in diastole respectively, left atrial 
dilatation was a z-score >+2 for left atrial diameter in systole and LVH was defined as maximal wall 
thickness of interventricular septum and/or LV posterior wall greater than +2 z-scores.[18] LV systolic 
function was assessed by Simpson’s Biplane method and an ejection fraction ≥ 55% was considered 
normal.[16] LV diastolic dysfunction was assessed through transmitral Doppler (peak early (E) and late 
diastolic (A) filling velocities), E/A ratio, deceleration time and pulmonary venous flow velocities including 
peak systolic (S) and diastolic (D) waves, S/D ratio and atrial reversal (Ar) velocity and paediatric reference 
ranges were used to define abnormality.[20] Patients were classified as having diastolic dysfunction when 
at least four parameters were abnormal.[21] RV systolic dysfunction was defined as a tricuspid annular 
plane systolic excursion (TAPSE) z-score of <-2.[18] Pulmonary hypertension was defined as present if the 
tricuspid regurgitation velocity was ≥2.9 m/s, estimated pulmonary arterial systolic pressure (PASP) ≥37 
mmHg with/without additional echocardiographic variables suggestive of pulmonary hypertension 
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(assuming right atrial pressure of 5mmHg).[22] PASP was indirectly calculated from the pressure gradient 
across the tricuspid valve (TV) by measuring the regurgitant jet and applying the simplified Bernoulli 
equation (4V2) and adding right atrial pressure (RAP) estimate to the tricuspid pressure gradient.[22] 
Hypoxia was defined as a resting oxygen saturation <88% or a ≥5% desaturation immediately following 
exercise; resting tachypnea was defined as a respiratory rate >25/min. Sinus tachycardia was defined as 
>130 beats per minute (bpm) for children aged 6-8 years and >110bpm for those aged 9-16 years.[23] 
Stunting and wasting were defined as a z-score <-2 for height-for-age and weight-for-age respectively, 
using British 1990 growth references.[24] Hypertension was defined as the systolic blood pressure and/or 
diastolic blood pressure ≥ 95th percentile; prehypertension was systolic blood pressure and/or diastolic 
blood pressure between the 90th and 95th percentile for age, gender and height.[25] Chronic lung disease 
was defined as having at least one of the following criteria:  chronic cough (≥ 3 months) with tuberculosis 
excluded; hypoxia (SpO2 <90% or desaturation ≥5% upon exertion); abnormal spirometry (defined as 
reduced ratio of the highest forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) 
(FEV1: FVC) or reduced FVC regardless of normal FEV1: FVC ratio)  irreversible with salbutamol[9] and 
MRC Dyspnoea scale >1.[26]  
Data management and statistical analysis 
Data were extracted from paper forms using optical character recognition software (Cardiff TELEFORM 
Intelligent Character, Version 10.7). Data were analyzed using STATA version 12 software (StataCorp, 
Texas, USA).  
A previous, retrospective, cross-sectional study in Zimbabwean adolescents found the prevalence of cardiac 
abnormalities to be between 24% and 67%.[27] We calculated a sample size of 200 was required to estimate 
an assumed prevalence of 65% with a precision of +/- 8% to 10%, for a 95% confidence interval. The 
association between HIV-related and clinical factors, determined a priori, and left and right cardiac 
abnormalities was investigated using multivariate logistic regression and odds ratios were calculated. Age 
and sex were included as a priori variables. HIV-related factors were categorized as follows: CD4 count 
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(>200 cells/μL and ≤200 cells/μL), HIV viral load (≤400 copies/ml and >400 copies/ml), age at ART 
initiation ( 0-5, 6-10 and 11-16 years), duration on ART (≤2 years and >2 years) and age was categorized 
as 6-10 years and 11-16 years. Antiretroviral drugs (ARVs), cardiac signs and symptoms, hypertension and 
chronic lung disease were dichotomized into yes and no. Zidovudine and nevirapine were selected because 
of evidence that zidovudine is associated with development of cardiomyopathy in children and nevirapine 
is associated with LVH in adults.[28, 29] Clinical factors evaluated include cardiac signs and symptoms, 
hypertension and chronic lung disease. Cardiac signs and symptoms included hypoxia, chest pains, 
tachypnoea and ankle swelling, and were grouped into one variable called cardiac symptoms. HIV-related 
variables that were significant at p≤0.1 on univariate logistic regression analysis were included in a 
multivariate logistic regression model. Clinical variables were added to the model and any clinical variable 
that was significant at p≤0.1 was retained for inclusion in the final model.   A value of p≤0.05 was 
considered statistically significant in the final model. Intra- and interobserver agreement was assessed 
through Bland-Altman plots.[30] Variability was estimated by calculating the mean (95% CI) of the 
arithmetic differences between repeated cardiac measures of the same participant. Normally distributed 
differences would fall within a range of mean ±1.96SD and the range is referred to as limits of agreement 
(LoA).  
Ethical approval was obtained from the Medical Research Council of Zimbabwe, the London School of 
Hygiene and Tropical Medicine Ethics Committee, the Biomedical Research and Training Institute 
Institutional Review Board and the Harare Central Hospital Ethics Committee.  Written informed consent 
from guardians and assent from participants was obtained prior to enrolment. Any abnormal findings during 
the course of the study were recorded in the child’s notes and the child was referred to a clinician on the 
same day for further management. 
Results 
Clinical characteristics 
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Of the 921 attendees to the clinic aged 6-16 years over the study period, 397 were eligible and of these, 201 
children were enrolled; the remainder were excluded due to the total number of enrolments being restricted 
to the first five eligible attendees per day (Figure 1). The median age was 11.1 years (IQR, 9-12) and 92 
(46%) were female. Mother-to-child transmission was assessed as the likely mode of HIV acquisition in all 
but one participant, in whom we speculate that HIV had been acquired through sexual transmission because 
the mother had tested HIV negative when the child was diagnosed at the age of 6 years. Participants were 
taking ART for a median duration of 4.7 years (IQR, 2.6-6.4) and 154/197 (78%) had an HIV VL<400 
copies/ml; the median CD4 count at enrolment was 727 cell/μl (IQR, 473-935) (n=198). No participant was 
taking any medication for cardiac disease. Eligible children who were not enrolled in the study were on 
average 5 months younger than those enrolled and had initiated ART at a year younger (Supplementary 
Table 1).  
Thirty-four (17%) children had a history of chest pain, 36/201 (18%) were in NYHA functional class >1 
and 24/198 (12%) had hypoxia. An abnormal blood pressure was observed in 106/198 (54%) children: 
85/106 (80%) had hypertension and 21/106 (20%) had prehypertension. Chronic cough was reported in 30 
(15%) and dyspnoea using the MRC dyspnoea scale in 30 (15%) and 42 (24%) had abnormal lung function 
on spirometry (Table 1). 
Echocardiographic findings 
Of the 201 enrolled participants, echocardiograms were performed on 197; the remaining four did not return 
for the examination. Echocardiographic measures are summarized in Table 2. Eighty-three (42%) 
participants had an echocardiographic abnormality of either the left and/or right heart. The most common 
abnormal finding was LV diastolic dysfunction in 45/197 (23%) children (Table 3). Isolated diastolic 
dysfunction, without associated LV dilatation or LVH, was observed in 33/45 (73%) children. LVH was 
the second most common finding in 22/197 (11%) with the following patterns: interventricular septal 
hypertrophy 2/22 (9%) and posterior wall hypertrophy 20/22 (91%). Seven children (32%) with LVH had 
diastolic dysfunction and global systolic function was impaired in one child. LV dilatation was observed in 
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9/197 (5%) children, one of whom had impaired systolic function and pericardial effusion. Left atrial 
dilatation was found in 16/197 (8%) children and of these 4 (25%) had LVH; 4 (25%) had diastolic 
dysfunction; and 2 (12%) had LV dilatation.   
RV dilatation was found in 13/197 (7%) and RV systolic dysfunction in 4/180 (2%) including two children 
with both RV dilatation and systolic dysfunction. Of the 15 participants who had RV abnormalities, nine 
(60%) had concurrent left heart abnormalities, including isolated LVH (n=2), isolated LV dilatation (n=1), 
isolated Left atrial dilatation (n=1), LV systolic dysfunction and LVH (n=1), isolated LV diastolic 
dysfunction (n=3) and one participant who had a dilated cardiomyopathy with LV and Left atrial dilatation 
and LV systolic dysfunction. Five (33%) of the participants with right heart abnormalities also met the case 
definition for chronic lung disease. None of the participants met the echocardiographic criteria for 
pulmonary hypertension. The prevalence of echocardiographic abnormalities was much higher when 
European reference ranges were used (Table 3).   
Twenty (10%) echocardiograms were used to determine inter-observer agreement. Bland-Altman plots 
showed that there was good agreement for repeated measures by the same observer two weeks apart and 
repeated measures between the two observers (Figure S1).  
Factors associated with echocardiographic abnormalities 
LV diastolic dysfunction was associated with hypertension (aOR 3.12 (1.48-6.57; p<0.01). Hypertension 
and LV diastolic dysfunction were present in 33/45 (73%) of the participants. LVH was associated with 
current use of nevirapine (aOR 3.14 (1.13-8.72; p=0.03) (Table 4). No HIV-related factors nor symptoms 
were associated with left atrial dilation. No associations were found between RV abnormalities and HIV-
related factors including CD4 count, viral load, duration on ART, age at ART initiation and lung function 
(supplementary Table 2).  
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Discussion 
This study demonstrates a high prevalence of echocardiographic abnormalities among HIV-infected 
children established on ART, more than three-quarters of whom were virologically suppressed.  Most of 
the participants with diastolic dysfunction had preserved systolic function. LV diastolic dysfunction is well 
described in adults with HIV but there are limited data on diastolic dysfunction in children. Diastolic 
parameters are difficult to measure in children and very slight alterations can result in significant changes 
in interpretation of the diastolic function. Interestingly, in the pre-ART era, systolic dysfunction and LV 
dilatation rather than impaired LV diastolic function were the predominant abnormalities observed, 
suggesting that LV diastolic impairment may be an earlier manifestation of cardiac disease.[31] It is not 
uncommon for diastolic dysfunction to present in isolation, typically before systolic impairment becomes 
apparent, for example in ischaemic cardiomyopathy.[32]  
Among those with LVH, LV posterior wall thickening was predominant, in keeping with our previous 
report.[27] Idris and colleagues found that children with HIV and exposed to ART had thicker LV posterior 
walls compared to ART- naïve children and larger LV dimensions compared to uninfected children.[33] 
LV dilatation was less common than LVH in our study. We found that current use of nevirapine was 
associated with LVH, which may suggest possible treatment induced effect on the myocardium. Nevirapine 
has been associated with LVH among HIV infected adults in Spain, most of whom were on ART and virally 
suppressed.[28]  
An important, previously unreported, abnormality found in our study was Left atrial dilatation, which is 
associated with adverse clinical outcomes such as atrial fibrillation and all-cause mortality in a range of 
cardiac disease, including ischaemic heart disease and hypertrophic cardiomyopathy.[34] Left atrial 
dilatation may occur because of increased LV filling pressures in the context of impaired LV diastolic 
function, for example among those with LVH, or because of LV dilatation.[34] Our data suggest that, in 
this population, Left atrial dilatation is related to the former. Further studies are required to investigate 
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whether Left atrial dilatation also represents a marker of increased risk of mortality among individuals 
living with HIV. 
More than half of the children had strikingly high blood pressure, but no association was found between 
LVH and abnormal blood pressure. However, we did find that LV diastolic dysfunction was associated with 
elevated blood pressure; hypertension is an established risk factor for LV diastolic dysfunction and a major 
contributor of heart disease.[35] However, not all patients with diastolic dysfunction had hypertension, 
suggesting a possible additional primary myocardial aetiology. Chatterton-Kirchmeier and colleagues also 
reported a high prevalence of elevated blood pressure among HIV-infected children and adolescents (age 
range 2-17 years), most of whom were on ART.[36] The reasons for this remain unclear, but this finding 
merits further investigation in this population. A high prevalence of elevated blood pressure in African 
children has been previously reported, in keeping with the present study.[37-40] There is a possibility of 
misclassification of participants as hypertensive; although we used the Fourth Report on the Diagnosis, 
Evaluation, and Treatment of High Blood Pressure in Children and Adolescents, we did not perform 
repeated measures of BP for our participants on separate visits.[25] Furthermore, there may have been an 
element of “white coat hypertension”.  Another explanation could be the possibility that the definition used 
for hypertension in this study, which is derived from reference ranges obtained from 70,000 children and 
adolescents from USA, is not suitable for the population under study.[25] Currently, there are no blood 
pressure references for African children. 
We found RV abnormalities (dilatation and systolic dysfunction) in 8% of the children. RV dilatation was 
the most common right sided abnormality, although lower than the 29% previously reported among 
Zimbabwean perinatally HIV-infected adolescents.[27] The former study enrolled older children aged 
between 10-19 years and included both ART naïve and ART-experienced children. Chelo and colleagues 
reported an even higher prevalence of RV dilatation (76%) among Cameroonian children aged 1–15 years, 
91% of whom were on ART. The  Zimbabwean study used European children’s references by Kampmann 
et al.[19]  and the Cameroonian study used  adults’ references as recommended by the ASE[41], and it is 
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possible that the prevalence of RV dilatation may have been overestimated in both studies. A comparison 
of African reference ranges, derived from Zimbabwean HIV-uninfected children and the European 
references by Kampmann et al.[19] and Huwez et al.[42] showed that RV diameters are higher among 
Black African children.[18] In this study we used locally developed reference ranges as a control population 
to define echocardiographic abnormalities.[18] European echocardiographic references derived from 
Caucasians[19] over-estimated the prevalence of some abnormalities in our cohort, underscoring the 
importance of using local reference ranges. Western reference ranges may not be appropriate and may 
explain the differences in prevalence of cardiac disease with the present study. 
We did not find any association between RV abnormalities and chronic lung disease or other HIV related 
factors and this may be due to a lack of power to detect the associations. More than half of the children with 
RV abnormalities had left heart abnormalities too, suggesting that the abnormalities in the right heart may 
be part of a global cardiomyopathic process. RV impairment may be secondary to left-sided 
cardiomyopathy and several mechanisms have been postulated, including the possibility that the same 
cardiomyopathic process may affect both ventricles.  Alternatively, LV failure may result in reduced 
coronary perfusion for both LV and RV, or the dilated LV may cause RV diastolic dysfunction due to 
cumulative pericardial limitation.[43]  
Most of the children in our study had normal RV systolic function despite having RV dilatation. Ventricular 
dilatation commonly occurs as an early structural change to maintain stroke volume when there is reduced 
wall motion.[44] It is possible that ventricular systolic dysfunction was subclinical and would clinically 
manifest over time.[45] 
None of the children had elevated PASP in our study, using Doppler echocardiography. Although Doppler 
echocardiography is recognised as an important tool for screening and assessment of patients at risk of 
pulmonary hypertension[46], right heart catheterisation is the gold standard in diagnosis of pulmonary 
hypertension, and recent reports have shown that Doppler echocardiography may under- or over-estimate 
pulmonary pressures, especially in children with elevated right heart pressures.[47] It is possible, therefore, 
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that right heart pressures may have been underestimated in our study. However, the concurrent right and 
left heart abnormalities in some of the children suggest that the observed RV abnormalities are not related 
to undiagnosed pulmonary hypertension but, rather, may reflect an underlying biventricular 
cardiomyopathic process. Further studies are required to investigate this.  
Although one fifth of the children reported one or more cardiac symptoms, most children with cardiac 
abnormalities were asymptomatic. These findings highlight the importance of regular cardiac screening in 
this population, even in the absence of symptoms. Myocardial disease is often subclinical and may only 
become symptomatic once it progresses and leads to significant cardiac dysfunction. Relying on symptoms 
alone without echocardiography screening may therefore result in delayed diagnosis of cardiac disease.  
Pathogenesis of cardiac disease in HIV infection is likely multifactorial. HIV causes dysregulated systemic 
activation which leads to chronic inflammation.  These mechanisms contribute to organ damage.  
Furthermore, damage to the immune system before subsequent access to ART maybe responsible for this 
long-term effect of cardiac abnormalities. Although the children in this study were stable on ART with high 
CD4 count and virally suppressed at the time of the study, low nadir CD4 count and/or opportunistic 
infections may have occurred and contributed to cardiac damage. Cardiotropic viruses including 
cytomegalovirus, coxsackievirus and Epstein-Barr virus have been reported to cause cardiac dysfunction in 
HIV [48] although we did not investigate presence of these viruses in these children. Deficiency of trace 
elements such as selenium have also been associated with HIV-associated cardiomyopathy,[49] but were 
not measured in this study. 
A major strength of this study was the systematic cardiological assessment, with echocardiography 
performed prospectively by a pediatric echocardiographer. Most importantly, we used local 
echocardiography reference ranges to define cardiac abnormalities.[18] Participants were not recruited 
selectively based on symptoms. Our study is limited by lack of data on global LV longitudinal strain, which 
may have been more sensitive to detecting subclinical LV systolic dysfunction, not apparent in the form of 
reduced LV ejection fraction. It is also limited by lack of a control group, but all cardiac abnormalities were 
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defined using reference measures derived locally. Local reference ranges were however, not available for 
blood pressure.  Hyperlipidemia is a recognized risk factor for cardiac disease, but we were unable to assess 
lipid profiles due to resource constraints. The children in this study did not undergo routine blood 
hemoglobin testing, although there was no clinical suspicion of anemia. The study is cross-sectional and 
may have been underpowered to detect any associations between risk factors and cardiac abnormalities. 
Due to the cross-sectional design, no causality can be attributed to the factors that were associated with 
cardiac abnormalities. 
In conclusion, our study demonstrates that there is a high burden of echocardiographic abnormalities in 
children, despite good control of HIV infection with ART. Our findings also suggest that right heart 
abnormalities in HIV-infected children on ART appear to be associated with abnormalities of the left heart. 
The impact and clinical course of these abnormalities and potential for reversibility still need to be 
investigated in prospective longitudinal studies. Further study of the pathogenesis of cardiac abnormalities 
will inform development of appropriate screening and therapeutic strategies for an increasing number of 
children growing up with HIV who face the prospect of taking lifelong ART. 
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Table 1: Baseline characteristics of participants (n=201) 
Variable N (%) unless otherwise stated 
Female 92 (46) 
Age, years (median, IQR) 11.1 (9 – 12) 
Age at HIV diagnosis, years (median, IQR) 5.1 (3-7) 
CD4, cell/μl (median, IQR) 726 (473-935) 
Viral load <400 copies/ml 154 (78) 
Duration on ART, y (median, IQR)  4.7 (2.6-6.4) 
Age at ART initiation, y (median, IQR) 6 (3-8) 
Treated for TB 74 (37) 
ART-Regimen  
2NRTIs + PI n 40 (19.9) 
2NRTIs + NNRTI n 154 (76.6) 
Unknown n 7 (3.5) 
Antiretroviral drugs§  
Zidovudine 105 (52) 
Nevirapine 103 (51) 
Symptoms and signs  
Chest pains on exertion  34 (17) 
Dizziness 19 (9) 
Tachycardia at rest 13 (6.5) 
Tachypnoea 14 (7.2) 
Hypoxia* 24 (12) 
Chronic cough 30 (15) 
Abnormal spirometry 42 (24) 
Ankle swelling 4 (2) 
Wasting  44 (22) 
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Stunting  48 (24) 
NYHA functional class >1  36 (18) 
Abnormal Blood Pressure† 106 (54) 
Pre-hypertension 21 (20) 
Hypertension 85 (80) 
High fasting glucose (>7) ‡ 2 (1) 
 
Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase; NNRTI, non-nucleoside reverse 
transcriptase; NYHA, New York heart association; IQR, interquartile range  
*missing data on n=3; †missing data on n=4; ‡missing data on n=7; § antiretroviral drugs evaluated in the logistic 
regression model 
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Table 2: Echocardiographic measures 
 
LV, left ventricle; IVS, interventricular septum, E/A ratio, mitral valve peak early to late left ventricular 
filling velocity; PV, pulmonary venous; S, systolic; D, diastolic; PASP, pulmonary arterial systolic 
pressure; TAPSE, tricuspid annular plane systolic excursion; * mean (SD) 
Measurement N=197 
Median (IQR)   
Body surface area (m2) 1.03 (0.92- 1.15) 
LV diameter z-score 0.68 (-0.22- 1.25) 
IVS diameter z-score 0.09 (0.66- 0.80) 
LV posterior wall z-score 0.28 (-0.51-1.07) 
Left atrium diameter z-score 0.32 (-0.44- 1.20) 
Fractional shortening (%) 31 (5.2) * 
Ejection Fraction (%) 62 (6.6) * 
E wave (m/s) 0.91 (0.81- 1.02) 
A wave (m/s) 0.53 (0.47- 0.60) 
E/A ratio 1.70 (1.50- 1.99) 
Deceleration Time (ms) 173 (156- 190) 
PV S wave (m/s) 0.49 (0.41-0.56) 
PV D wave (m/s) 0.50 (0.46- 0.57) 
PV A wave (m/s) 0.18 (0.16- 0.21) 
PV S/D ratio 0.96 (0.79- 1.16) 
RV diameter, z-score  0.37 (-0.52 -1.28) 
PASP, mmHg 12.8 (8.7 -16.9) 
TAPSE, z-score -0.73 (-1.44 - -0.09) 
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Table 3: Proportions of cardiac abnormalities 
Abnormalities Local references* [18] 
N=197 
N (%) 
European references [19] 
N=197 
N (%) 
LV dilatation  9 (5) 9 (5) 
LVH 22 (11) 73 (37) 
- Interventricular septal hypertrophy 2 (9) 52 (71) 
- Posterior wall hypertrophy  20 (91) 
 
4 (6) 
- Concentric hypertrophy - 17 (23) 
Left atrial dilatation  16 (8) 12 (6) 
LV systolic dysfunction 3 (2) 3 (2) 
LV diastolic dysfunction 45 (23) 45 (23) 
RV dilatation 13 (7) 57 (29) 
RV systolic dysfunction 4 (2) - 
Any echocardiographic abnormality 83 (42)  
Any left heart abnormality 77 (39)  
Any right heart abnormality 15 (8)   
 
*, local reference ranges were used as the primary basis of defining cardiac abnormalities. 
Abbreviations: LA, left atrium; LV, left ventricle; LVH, left ventricular hypertrophy; RV, right ventricular 
missing data on n=4 
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Table 4: Factors associated with left heart abnormalities 
Variable  LV Diastolic Dysfunction LVH 
 Prevalence Unadjusted Adjusted Prevalence Unadjusted Adjusted 
 n/N (%) OR (95% CI) p-value OR (95% CI) P-value n/N (%) OR (95% CI) P-value OR (95% CI) P-value 
Sex           
Female 20/94 (21 1    14/94 (15) 1    
Male 25/103 (24) 0.19 (0.16-2.31) 0.61   8/103 (8) 0.48 (0.12-1.21) 0.12   
Age           
6-10 years 25/91 (27) 1    10/91 (11) 1    
11-16 years 20/106 (19) 0.61 (0.31-1.20) 0.15   12/106 (11) 1.03 (0.42-2.52) 0.94   
Age at ART initiation           
0-5 years 27/93 (29) 1.91 (0.93-3.90) 0.08 1.95 (0.93-4.07) 0.08 13/93 (14) 2.14 (0.77-5.91) 0.14   
6-10 years 15/85 (18) 1  1  6/85 (7) 1    
11-16 years 3/17 (18) 1.00 (0.26-3.92) 1 1.14 (0.28-4.64)  3/17 (18) 2.82 (0.63-12.6) 0.18   
Duration on ART           
≤ 2 years 10/55 (18) 1    6/55 (11) 1    
>2 years 35/142 (25) 1.47 (0.67-3.22) 0.33   16/142 (11) 1.04 (0.38-2.80) 0.94   
CD4 count           
>200 cell/μl 44/187 (24) 1    21/187 (11) 1    
≤200 cell/μl 1/9 (11) 0.41 (0.05-3.34) 0.40   1/9 (11) 0.99 (0.12-8.30) 0.99   
Viral load           
24 
 
24 
 
≤400 copies/ml 35/152 (23) 1    18/152 (12) 1    
>400 copies/ml 9/41 (22) 1.06 (0.46-2.44) 0.88   3/41 (7) 1.70 (0.48-6.08) 0.41   
Nevirapine *           
No 22/98 (22) 1    6/98 (6) 1    
Yes 23/99 (23) 1.05 (0.54-2.03) 0.90   16/99 (16) 2.96 (1.10-7.91) 0.03 3.14 (1.13-8.72) 0.03 
Zidovudine*           
No 17/95 (18) 1    8/95 (8) 1    
Yes 28/102 (27) 1.74 (0.89-3.43) 0.11   14/102 (14) 1.73 (0.69-4.33) 0.242   
Cardiac symptoms†           
No 27/119 (23) 1    13/119 (10) 1    
Yes 18/78 (23) 1.02 (0.52-2.02) 0.95   9/78 (12) 1.06 (0.43-2.62) 0.89   
Hypertension           
No 12/92 (13) 1    12/92 (13) 1    
Yes 33/103 (32) 3.14 (1.51-6.55) <0.01 3.12 (1.48-6.57) <0.01 10/103 (10) 0.72 (0.29-1.75) 0.46   
 
ART, antiretroviral therapy; LV, left ventricular; LVH, left ventricular hypertrophy * Antiretroviral drugs; † cardiac signs and symptoms included hypoxia, chest 
pains, tachypnoea, and ankle swelling
25 
 
25 
 
Figure 1: Participant Recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV+ Screened  
N=921 
 
1 Withdrew 
 
341 Unaccompanied by guardian  
32 Not residing in Harare 
51-no consent 
59 Not on ART 
39 On ART <6 months 
2 TB treatment <8 weeks  
 
Eligible for recruitment  
N=397 
 
Study procedures  
197 Echocardiography 
197 Clinical assessment 
200 CD4 count 
199 Viral load 
200 spirometry (n=177 met QC criteria) 
 
Recruited  
202 
 
195: not recruited because the first 
5 had already been taken 
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Supplementary Figure 1: Bland-Altman plots for intra-and interobserver agreement for cardiac measures 
A: Intra-observer agreement Bland-Altman plots 
 
 
B: Inter-observer agreement plots 
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Supplementary Table 1: Factors associated with enrolment in the study 
Variable Enrolled 
N=200 
Not enrolled 
N=197 
Test coefficient, p-value 
Age, y, mean (SD) 10.5 (2.5) 9.9 (2.7) t=-2.20, p=0.03 
Sex, n (%) female 
                    
96 (48.0) 
 
86 (43.7) Chi2=0.75, p=0.39 
Taking TB treatment, n (%) 1 (0.5) 1 (0.5) Chi2=0.00, p=0.99 
Age at ART initiation, y, mean 
(SD) 
6.1 (3.2) 5.1 (3.3) t=-3.04, p=0.003 
 
SD, standard deviation; TB, tuberculosis; ART, antiretroviral therapy 
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Supplementary Table 2: Factors associated with RV abnormalities 
Variable RV abnormalities 
 Prevalence Unadjusted  
 n/N (%) OR (95% CI) P-value 
Sex    
Female 9/94 (9) 1  
Male 6/103 (5) 0.58 (0.20- 1.71) 0.33 
Age    
6-10 years 6/91 (7) 1  
11-16 years 9/106 (8) 1.31 (0.45- 3.84) 0.50 
Age at ART initiation    
0-5 years 6/93 (6) 0.77 (0.25-2.38) 0.65 
6-10 years 7/85 (8) 1  
11-16 years 2/17 (12) 1.49 (0.28-7.86) 0.64 
Duration on ART    
≤ 2 years 5/55 (9) 1  
>2 years 10/142 (7) 0.80 (0.28- 2.30)                   0.6 
CD4 count    
>200 cell/μl 14/187 (7) 1  
≤200 cell/μl 0 - - 
Viral load    
≤400 copies/ml 15/152 (10) 1  
>400 copies/ml 0 - - 
Nevirapine *    
No 9/98 (9) 1  
Yes 6/99 (6) 0.64 (0.22-1.87) 0.41 
Zidovudine*    
No 8/95 (8) 1  
Yes 7/102 (7) 0.80 (0.28-2.30) 0.68 
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Cardiac symptoms†    
No 9/119 (8) 1  
Yes 6/78 (8) 1.02 (0.35-2.98) 0.97 
Hypertension    
No 8/92 (9) 1  
Yes 7/103 (7) 0.77 (0.27-2.20) 0.62 
Chronic lung disease    
No 10/121 (8) 1  
Yes 5/76 (7) 0.78 (0.26-2.38) 0.67 
 
ART, antiretroviral therapy; RV, right ventricular; * Antiretroviral drugs; † cardiac signs and symptoms included 
hypoxia, chest pains, tachypnoea, and ankle swelling 
